GFAP and type 1 diabetes mellitus: The current study demonstrated that GFAP expression was used to demonstrate SGC activation in various models of traumatic nerve injury [26] as well as in models of type 1 diabetes [27], ischemia [28], facial cancer [29], chemotherapy administration [30,31], and peripheral inflammation [32].